Final Program

Recommendations

Info

322 TUESDAY • MAY 17 2:45 Long-Term Exposure to Ozone and Accelerated Progression of Percent Emphysema and Decline in Lung Function: The MESA Air and Lung Studies/M. Wang, R.G. Barr, E.A. Hoffman, J. Madrigano, C.P. Aaron, P.D. Sampson, L. Sheppard, S. Vedal, J. Kaufman, Seattle, WA, p.A6163 3:00 Genetic Ancestry is Associated with Baseline Lung Function, CT-Scan Emphysema, and COPD Risk in African Americans and Hispanics from SPIROMICS/V.E. Ortega, E.A. Hoffman, E.J. Ampleford, G.A. Hawkins, R.G. Barr, D.J. Couper, M.K. Han, R. Kanner, E. Kleerup, F.J. Martinez, S.I. Rennard, P.G. Woodruff, D.A. Meyers, E.R. Bleecker, Winston-Salem, NC, p.A6164 3:15 Associations Between Smoking, Telomere Length and Lung Function Decline: Findings from a Population-Based Longitudinal Study/P. Andujar, D. Courbon, E. Bizard, E. Marcos, S. Adnot, P. Demoly, I. Pin, G. Thabut, J. Boczkowski, B. Leynaert, Creteil, France, p.A6165 3:30 Lung Cancer-Specific Mortality Reduction With CT Screening: Outcomes According to Airflow Limitation in the ACRIN NLST Sub-Study (N=18,475)/R.P. Young, F. Duan, E. Greco, R.J. Hopkins, C. Chiles, G.D. Gamble, D. Aberle, Auckland, New Zealand, p.A6166 3:45 Microalbuminuria Predicts the Incidence of Severe Chronic Lower Respiratory Disease Exacerbations in Older Adults: The Multi-Ethnic Study of Atherosclerosis (MESA)-Lung Study/E.C. Oelsner, M.E. Grams, D.R. Jacobs, Jr., R. Kronmal, G.T. O’Connor, D. Rabinowitz, R.P. Tracy, R.G. Barr, New York, NY, p.A6167 4:00 Blood Eosinophils Poorly Correlate with Sputum Eosinophils, and Have Few Associations with Spirometry, Clinical and Quantitated Computed Tomography Measures Compared to Sputum Eosinophils in the SPIROMICS Cohort/A.T. Hastie, N.E. Alexis, C. Doerschuk, N.N. Hansel, S. Christenson, N. Putcha, V.E. Ortega, S.P. Peters, MD, PhD, R.G. Barr, D.J. Couper, E.A. Hoffman, R. Kanner, E. Kleerup, F.J. Martinez, P.G. Woodruff, M.K. Han, D.A. Meyers, J.L. Curtis, E.R. Bleecker, Winston-Salem, NC, p.A6168 C98 MINI SYMPOSIUM AIRWAY REMODELING IN COPD AND ASTHMA 2:15 p.m. - 4:15 p.m. MOSCONE CENTER Room 2016/2018 (West Building, Level 2) Chairing: T. Hackett, PhD, Vancouver, Canada H. Meurs, PhD, Groningen, Netherlands A.L. James, MD, MBBS, PhD, Nedlands, Australia Oral Presentations 2:15 Investigating the Features of Small Airway Obstruction in COPD: Obstructed Small Airways Are an Early Feature of Mild and Moderate Disease/S. Booth, H.-K. Koo, D.M. Vasilescu, L. Mostaco-Guidolin, J.C. Hogg, T.-L. Hackett, Vancouver, Canada, p.A6169 2:30 Brain Derived Neurotrophic Factor Effects on Asthmatic Airway Smooth Muscle: A Profile of Epigenetic Regulation/ L.J. Manlove, G.R. Saint-Croix, M. Freeman, M.A. Thompson, C. Pabelick, Y.S. Prakash, Rochester, MN, p.A6170 2:45 Quantitative Assessment of Airway Remodeling with Birefringence Microscopy: Phenotyping Asthma/M.J. Suter, D.C. Adams, L.P. Hariri, A.J. Miller, J.A. Holz, M.V. Szabari, R.S. Harris, J.L. Cho, J.W. Griffith, D.L. Hamilos, A.D. Luster, B.D. Medoff, Boston, MA, p.A6171 3:00 Heterogeneity of Airway Remodeling Contributes to Airway Hyperresponsiveness in Asthma/C.D. Pascoe, P.D. Pare, G.M. Donovan, Winnipeg, Canada, p.A6172 3:15 Novel Non-Linear Optical Imaging to Understand the Composition of Fibrilar Collagen and Elastin in Remodeled Asthmatic Airways/L.B. Mostaco-Guidolin, E.T. Osei, S. Hajimohammadi, J. Ullah, T.-L. Hackett, Vancouver, Canada, p.A6173 3:30 Mast Cell Tryptase Activates Matrix Metalloproteinase-1 Causing Matrix Remodelling, Airway Smooth Muscle Growth and Airway Obstruction During Asthma Exacerbations/S. Naveed, D.J. Jackson, D. Clements, C. Reynolds, D. Shaw, S.L. Johnston, S.R. Johnson, Nottingham, United Kingdom, p.A6174 3:45 Fibulin-1 Plays Critical Roles in the Pathogenesis of Pulmonary Diseases/P.M. Hansbro, G. Liu, M.A. Cooley, A.G. Jarnicki, A.C.-Y. Hsu, P.M. Nair, T.J. Haw, M. Fricker, S.L. Gellatly, R.Y. Kim, M.D. Inman, G. Tjin, P.A. Wark, J.C. Horvat, B.G. Oliver, W.S. Argraves, D.A. Knight, J.K. Burgess, New Lambton Heights, Australia, p.A6175 4:00 MMP-13 is a Critical Driver of Lung Destruction in a Viral Exacerbation Model of COPD/M.P. Goldklang, F. Cvetkovski, D. Turner, R. Xiao, T. Zelonina, K. Stearns, J. Trischler, P. Sklepkiewicz, P. Elkington, D. Farber, J. D’Armiento, New York, NY, p.A6176 C99 MINI SYMPOSIUM BEYOND THE NATIONAL LUNG SCREENING TRIAL 2:15 p.m. - 4:15 p.m. MOSCONE CENTER Chairing: C.G. Slatore, MD, Portland, OR M.K. Gould, MD, MS, Pasadena, CA Featured Speaker Room 306/308 (South Building, Esplanade Level) 2:15 The Future of Lung Cancer Screening/R.S. Wiener, MD, MPH, Boston, MA, Oral Presentations 2:30 Using Electronic Health Records to Assess Eligibility for Lung Cancer Screening: An Examination of Capture and Reliability of Smoking History Data/L. Sakoda, G. Minowada, G. Mogel, V. Lee, N. Gordon, P. Doria-Rose, L. Kushi, L. Habel, Oakland, CA, p.A6177 2:45 Airflow Limitation and Lung Cancer Risk in a Large Prospective Screening Study (NLST-ACRIN Cohort Analysis, N=18, 714)/R.J. Hopkins, R.P. Young, F. Duan, C. Chiles, E. Greco, G.D. Gamble, D. Aberle, Auckland, New Zealand, p.A6178 ATS 2016 • San Francisco
TUESDAY • MAY 17 323 3:00 Racial and Gender Disparities for Curative Lung Cancer Surgery in the National Lung Screening Trial/A.A. Balekian, Los Angeles, CA, p.A6179 3:15 Estimating the Benefit of CT Screening for Metachronous Lung Cancer/K.L. Hamlington, C.M. Kinsey, J.C. O’Toole, R.D. Stapleton, J.H.T. Bates, Burlington, VT, p.A6180 3:30 Impact of a Bronchial Genomic Classifier on Clinical Decision Making in Patients Undergoing Diagnostic Evaluation for Lung Cancer/J.S. Ferguson, R. Van Wert, Y. Choi, M. Rosenbluth, J. Huang, A. Spira, Madison, WI, p.A6181 3:45 Cost-Effectiveness of the Percepta Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer: An Analytical Framework Based on the AEGIS Studies/D.J. Feller-Kopman, S. Liu, A.M. Garner, M. Decamp, J.B. Pietzsch, Baltimore, MD, p.A6182 4:00 Diagnostic Evaluation of the Indeterminate Pulmonary Nodule Among Military and Veteran Personnel with Suspect Lung Cancer: The DECAMP Consortium/E. Billatos, M. Muse, A. Jiwani, I. Mahon, E. Maple, C.W. Atwood, C. Apgar, J.T. Battaile, R. Browning, E. Garshick, R.H. Goldstein, R.L. Keith, K. More, M. Morris, J.S. Parrish, M. Reid, C. Gatsonis, D. Elashoff, F. Duan, S.M. Dubinett, M. Lenburg, P.P. Massion, D. Remick, I.I. Wistuba, M. Schnall, A. Vachani, A. Spira, Boston, MA, p.A6183 C101 SARCOIDOSIS POSTER DISCUSSION SESSION 2:15 p.m. - 4:15 p.m. MOSCONE CENTER Room 3014 (West Building, Level 3) Poster Viewing 2:15-3:00 Discussion 3:00-4:15 Chairing: M.A. Judson, MD, Albany, NY A.S. Morgenthau, MD, New York, NY E.S. Chen, MD, Baltimore, MD 901 The Foundation for Sarcoidosis Research Sarcoidosis Advanced Registry for Cures/L. Serchuck, G. Spitzer, M. Rossman, R.P. Baughman, D.A. Culver, M. Drent, C. Lipset, B. Stern, Chicago, IL, p.A6184 902 Comparison of Cardiac Magnetic Resonance Imaging and 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography Used for Diagnostic Assessment of Cardiac Involvement in Suspected Cardiac Sarcoidosis Patients/V. Kouranos, R. Sharma, M. Kokosi, J. Baksi, S. Prasad, R. Khattar, K. Wechalekar, A.U. Wells, London, United Kingdom, p.A6185 903 Pulmonary Sarcoidosis Phenotypes: Using Cluster Analysis/M.M. Banoei, N. Sweiss, R.P. Baughman, B.W. Winston, Calgary, Canada, p.A6186 904 The Impact of Age and Left Ventricular Function on Survival in Cardiac Sarcoidosis/Y. Zhou, H. Li, E. Lower, A. Costea, M. Attari, R.P. Baughman, Shanghai, China, p.A6187 905 Clinical Characteristics of Sarcoidosis Patients in America and China/Y. Zhou, H. Li, E. Lower, Shanghai, China, p.A6188 906 A Novel In Vitro Human Model of Sarcoidosis/E.D. Crouser, E. Guirado, M.W. Julian, W. Sadee, A. Papp, A. Friedman, P. White, L. Schlesinger, Columbus, OH, p.A6189 907 Stepwise Approach to Bronchoscopic Diagnosis of Sarcoidosis in Patients with Intrathoracic Adenopathy Employing EBUS, ROSE, and Histology Needles/C. Oberg, T.J. Harkin, New York, NY, p.A6190 908 The Complimentary Role of Transbronchial Cryobiopsy Versus Endobronchial Utrasound (EBUS) for Diagnosing Pulmonary Sarcoidosis/S. Benzaquen, A. Aragaki, T.S. Sripasart, D. Tanase, G. Khana, M. Kirschner, R.P. Baughman, Cincinnati, UT, p.A6191 909 Predicting the Course of Sarcoidosis in the Initial Evaluation/M. Castro, P. Gomes, R.C. Tibana, B. Beraldo, A. Gimenez, C. Fukuda, R. Ferreira, M.R. Soares, C.A. Pereira, Sao Paulo, Brazil, p.A6192 910 The Use of Registry for Sarcoidosis Associated Pulmonary Hypertension (ReSAPH) in the Design of the Riociguat for Sarcoidosis Associated Pulmonary Hypertension (RioSAPH)/R.P. Baughman, S.D. Nathan, P. Engel, J.B. Barney, M.B. Scholand, D.A. Culver, Cincinnati, OH, p.A6193 911 Can the Sarcoidosis Health Questionnaire Predict the Shortand Long-Term Outcomes of Patients with Chronic Sarcoidosis?/K. Tanizawa, T. Handa, S. Nagai, T. Oga, T. Kubo, Y. Ito, K. Aihara, K. Ikezoe, A. Sokai, Y. Nakatsuka, T. Hirai, K. Chin, M. Mishima, T. Izumi, Kyoto, Japan, p.A6194 912 Quality of Life Impairment and Fatigue Are Not Correlated with Mean Pulmonary Artery Pressure in Patients with Sarcoidosis Associated Pulmonary Hypertension/E.M. Carmona, S. Kalra, J.B. Barney, O.A. Shlobin, D.A. Culver, M.B. Scholand, K. Vasilis, E.H. Alhamad, F. Cordova, B. Van Den Blink, R.P. Baughman, Rochester, MN, p.A6195 913 Correlation Between Serum Biomarkers (ACE and Chitotriosidase) and 18F-FDG PET/CT )-Follow Up Study/V. Mihailovic-Vucinic, S. Filipovic-Stepic, J.L. Videnovic Ivanov, M. Stjepanovic, B. Gvozdenovic, Z. Sumarac, Belgrade, Serbia, p.A6196 914 Relation of Neutrophil/Lymphocyte Ratio with Radiological Extent in Pulmonary Sarcoidosis/N. Ocal, D. Dogan, R. Ocal, E. Tozkoparan, O. Deniz, E. Ucar, S. Gumus, C. Tasci, A. Taskin, U. Turhan, Ankara, Turkey, p.A6197 915 The Morphological Feature of Alveolar Macrophage Form on Bronchoalveolar Lavage Fluid in Patients with Sarcoidosis/M. Ishida, H. Ishii, S. Wada, T. Koide, T. Saraya, R. Tazawa, K. Nakata, H. Takizawa, Mikata, Japan, p.A6198 916 Sarcoidosis in Patients with Previous Malignancy/R. Kuint, N. Arish, E. Sapir, L. Levy, A. Abutbul, Z.G. Fridlender, U. Laxer, N. Berkman, Jerusalem, Israel, p.A6199 917 A Novel Method to Quantitate Fluorodeoxyglucose by Positron Emission Tomography (PET) in the Lung Parenchyma of Sarcoidosis Patients/R. Keijsers, N. Sweiss, L.A. Saketkoo, E. Lower, R.P. Baughman, Utrecht, Netherlands, p.A6200 TUESDAY AFTERNOON ATS 2016 • San Francisco
Page 1 and 2:
American Thoracic Society Internati
Page 3:
TABLE OF CONTENTS ATS 2016 INTERNAT
Page 6 and 7:
2 FRIDAY • MAY 13 PG2A CLINICAL P
Page 8 and 9:
4 FRIDAY • MAY 13 Target Audience
Page 10 and 11:
6 FRIDAY • MAY 13 11:15 Case Disc
Page 12 and 13:
8 FRIDAY • MAY 13 Chairing: H.B.
Page 14 and 15:
10 FRIDAY • MAY 13 10:25 Advanced
Page 16 and 17:
12 FRIDAY • MAY 13 Objectives At
Page 18 and 19:
14 SATURDAY • MAY 14 Abdominal Ul
Page 20 and 21:
16 SATURDAY • MAY 14 PG17 BASIC
Page 22 and 23:
18 SATURDAY • MAY 14 1:05 In What
Page 24 and 25:
20 SATURDAY • MAY 14 10:30 Practi
Page 26 and 27:
22 SATURDAY • MAY 14 Objectives A
Page 28 and 29:
24 SATURDAY • MAY 14 10:10 Is My
Page 30 and 31:
26 SUNDAY • MAY 15 Chairing: D.M.
Page 32 and 33:
28 SUNDAY • MAY 15 Chronic Cough:
Page 34 and 35:
30 SUNDAY • MAY 15 • understand
Page 36 and 37:
32 SUNDAY • MAY 15 Target Audienc
Page 38 and 39:
34 SUNDAY • MAY 15 Oral Presentat
Page 40 and 41:
36 SUNDAY • MAY 15 9:15 Hyperpola
Page 42 and 43:
38 SUNDAY • MAY 15 310 A Smartpho
Page 44 and 45:
40 SUNDAY • MAY 15 103 Immunosupp
Page 46 and 47:
42 SUNDAY • MAY 15 A26 POSTER DIS
Page 48 and 49:
44 SUNDAY • MAY 15 822 Incidence
Page 50 and 51:
46 SUNDAY • MAY 15 519 Maternal H
Page 52 and 53:
48 SUNDAY • MAY 15 P14 P15 P16 P1
Page 54 and 55:
50 SUNDAY • MAY 15 P1545 P1546 Fa
Page 56 and 57:
52 SUNDAY • MAY 15 P60 P61 Facili
Page 58 and 59:
54 SUNDAY • MAY 15 P149 P150 Faci
Page 60 and 61:
56 SUNDAY • MAY 15 P749 P750 P751
Page 62 and 63:
58 SUNDAY • MAY 15 Facilitator: P
Page 64 and 65:
60 SUNDAY • MAY 15 P1243 P1244 P1
Page 66 and 67:
62 SUNDAY • MAY 15 P1295 P1296 P1
Page 68 and 69:
64 SUNDAY • MAY 15 P1358 P1359 P1
Page 70 and 71:
66 SUNDAY • MAY 15 P91 Facilitato
Page 72 and 73:
68 SUNDAY • MAY 15 P616 P617 P618
Page 74 and 75:
70 SUNDAY • MAY 15 P914 P915 P916
Page 76 and 77:
72 SUNDAY • MAY 15 P556 P557 P558
Page 78 and 79:
74 SUNDAY • MAY 15 Facilitators:
Page 80 and 81:
76 SUNDAY • MAY 15 P997 P998 P999
Page 82 and 83:
78 SUNDAY • MAY 15 P256 P257 P258
Page 84 and 85:
80 SUNDAY • MAY 15 A61 THEMATIC P
Page 86 and 87:
82 SUNDAY • MAY 15 P824 Facilitat
Page 88 and 89:
84 SUNDAY • MAY 15 P1055 P1056 P1
Page 90 and 91:
86 SUNDAY • MAY 15 P1101 P1102 P1
Page 92 and 93:
88 SUNDAY • MAY 15 P1423 P1424 P1
Page 94 and 95:
90 SUNDAY • MAY 15 P1474 P1475 P1
Page 96 and 97:
92 SUNDAY • MAY 15 P377 P378 P379
Page 98 and 99:
94 SUNDAY • MAY 15 P281 P282 P283
Page 100 and 101:
96 SUNDAY • MAY 15 P450 P451 A74
Page 102 and 103:
98 SUNDAY • MAY 15 P1562 P1563 P1
Page 104 and 105:
100 SUNDAY • MAY 15 A80-A THEMATI
Page 106 and 107:
102 SUNDAY • MAY 15 Facilitator:
Page 108 and 109:
104 SUNDAY • MAY 15 11:00 a.m.-12
Page 110 and 111:
106 SUNDAY • MAY 15 L1 U.S. FOOD
Page 112 and 113:
108 SUNDAY • MAY 15 12:15 Post-Pr
Page 114 and 115:
110 SUNDAY • MAY 15 MP406 MP407 M
Page 116 and 117:
112 SUNDAY • MAY 15 clinician and
Page 118 and 119:
114 SUNDAY • MAY 15 A86 BASIC •
Page 120 and 121:
116 SUNDAY • MAY 15 Chairing: M.J
Page 122 and 123:
118 SUNDAY • MAY 15 3:30 High Pre
Page 124 and 125:
120 SUNDAY • MAY 15 102 Toll-Like
Page 126 and 127:
122 SUNDAY • MAY 15 A103 POSTER D
Page 128 and 129:
124 SUNDAY • MAY 15 719 Lactate R
Page 130 and 131:
126 SUNDAY • MAY 15 1014 Determin
Page 132 and 133:
128 SUNDAY • MAY 15 611 Plasma Mi
Page 134 and 135:
130 SUNDAY • MAY 15 412 Daytime S
Page 136 and 137:
132 SUNDAY • MAY 15 6:30 p.m. - 8
Page 138 and 139:
134 MONDAY • MAY 16 SS111 SS112 S
Page 140 and 141:
136 MONDAY • MAY 16 Target Audien
Page 142 and 143:
138 MONDAY • MAY 16 9:40 Empoweri
Page 144 and 145:
140 MONDAY • MAY 16 9:28 Endotoxi
Page 146 and 147:
142 MONDAY • MAY 16 10:15 Adaptiv
Page 148 and 149:
144 MONDAY • MAY 16 Oral Presenta
Page 150 and 151:
146 MONDAY • MAY 16 624 Neonatal
Page 152 and 153:
148 MONDAY • MAY 16 118 Compariso
Page 154 and 155:
150 MONDAY • MAY 16 912 Should Pa
Page 156 and 157:
152 MONDAY • MAY 16 1015 Resverat
Page 158 and 159:
154 MONDAY • MAY 16 718 Health Re
Page 160 and 161:
156 MONDAY • MAY 16 P152 Facilita
Page 162 and 163:
158 MONDAY • MAY 16 B35 THEMATIC
Page 164 and 165:
160 MONDAY • MAY 16 P252 P253 P25
Page 166 and 167:
162 MONDAY • MAY 16 P406 P407 P40
Page 168 and 169:
164 MONDAY • MAY 16 P320 Bilatera
Page 170 and 171:
Page 172 and 173:
168 MONDAY • MAY 16 P528 P529 Fac
Page 174 and 175:
170 MONDAY • MAY 16 Facilitator:
Page 176 and 177:
Page 178 and 179:
174 MONDAY • MAY 16 P484 P485 P48
Page 180 and 181:
176 MONDAY • MAY 16 P1161 P1162 P
Page 182 and 183:
Page 184 and 185:
180 MONDAY • MAY 16 P1238 P1239 P
Page 186 and 187:
182 MONDAY • MAY 16 P1297 P1298 P
Page 188 and 189:
Page 190 and 191:
186 MONDAY • MAY 16 P15 P16 P17 P
Page 192 and 193:
Page 194 and 195:
190 MONDAY • MAY 16 P114 P115 P11
Page 196 and 197:
192 MONDAY • MAY 16 P1408 Enhance
Page 198 and 199:
194 MONDAY • MAY 16 P1455 P1456 P
Page 200 and 201:
196 MONDAY • MAY 16 P1487 P1488 P
Page 202 and 203:
198 MONDAY • MAY 16 P1514 P1515 P
Page 204 and 205:
Page 206 and 207:
202 MONDAY • MAY 16 P559 P560 P56
Page 208 and 209:
204 MONDAY • MAY 16 WS3 CLINICAL
Page 210 and 211:
206 MONDAY • MAY 16 Satellite ear
Page 212 and 213:
208 MONDAY • MAY 16 Objectives At
Page 214 and 215:
210 MONDAY • MAY 16 encourage tra
Page 216 and 217:
212 MONDAY • MAY 16 B82 BEHAVIORA
Page 218 and 219:
214 MONDAY • MAY 16 B86 BASIC •
Page 220 and 221:
216 MONDAY • MAY 16 and a number
Page 222 and 223:
218 MONDAY • MAY 16 2:30 Mortalit
Page 224 and 225:
220 MONDAY • MAY 16 3:00 Simultan
Page 226 and 227:
222 MONDAY • MAY 16 525 Clinical
Page 228 and 229:
224 MONDAY • MAY 16 320 Sensitivi
Page 230 and 231:
226 MONDAY • MAY 16 113 COPD Subt
Page 232 and 233:
228 MONDAY • MAY 16 1004 Health C
Page 234 and 235:
230 MONDAY • MAY 16 609 Skeletal
Page 236 and 237:
232 MONDAY • MAY 16 5:00 p.m. - 7
Page 238 and 239:
234 TUESDAY • MAY 17 Chairing: D.
Page 240 and 241:
236 TUESDAY • MAY 17 CLINICAL YEA
Page 242 and 243:
238 TUESDAY • MAY 17 This session
Page 244 and 245:
240 TUESDAY • MAY 17 bronchiectas
Page 246 and 247:
242 TUESDAY • MAY 17 Target Audie
Page 248 and 249:
244 TUESDAY • MAY 17 C18 MINI SYM
Page 250 and 251:
246 TUESDAY • MAY 17 415 Investig
Page 252 and 253:
248 TUESDAY • MAY 17 207 Survival
Page 254 and 255:
250 TUESDAY • MAY 17 906 Phenotyp
Page 256 and 257:
252 TUESDAY • MAY 17 807 The Vali
Page 258 and 259:
254 TUESDAY • MAY 17 515 Roles of
Page 260 and 261:
256 TUESDAY • MAY 17 P383 P384 P3
Page 262 and 263:
258 TUESDAY • MAY 17 Facilitator:
Page 264 and 265:
260 TUESDAY • MAY 17 P199 P200 P2
Page 266 and 267:
262 TUESDAY • MAY 17 P620 Facilit
Page 268 and 269:
264 TUESDAY • MAY 17 P428 P429 P4
Page 270 and 271:
266 TUESDAY • MAY 17 P442 P443 P4
Page 272 and 273:
268 TUESDAY • MAY 17 P318 P319 P3
Page 274 and 275:
270 TUESDAY • MAY 17 P474 P475 Fa
Page 276 and 277: 272 TUESDAY • MAY 17 Facilitator:
Page 278 and 279: 274 TUESDAY • MAY 17 P727 P728 P7
Page 280 and 281: 276 TUESDAY • MAY 17 P774 P775 Fa
Page 282 and 283: 278 TUESDAY • MAY 17 C53 THEMATIC
Page 286 and 287: 282 TUESDAY • MAY 17 P1095 P1096
Page 308 and 309: 304 TUESDAY • MAY 17 P973 P974 Fa
Page 316 and 317: 312 TUESDAY • MAY 17 • become a
Page 318 and 319: 314 TUESDAY • MAY 17 The topics a
Page 320 and 321: 316 TUESDAY • MAY 17 C85 BASIC
Page 322 and 323: 318 TUESDAY • MAY 17 C89 BASIC
Page 324 and 325: 320 TUESDAY • MAY 17 3:20 Pediatr
Page 328 and 329: 324 TUESDAY • MAY 17 918 Sarcoido
Page 330 and 331: 326 TUESDAY • MAY 17 410 Effectiv
Page 332 and 333: 328 TUESDAY • MAY 17 710 Follista
Page 334 and 335: 330 TUESDAY • MAY 17 509 A Mechan
Page 336 and 337: 332 TUESDAY • MAY 17 806 Upper Ai
Page 338 and 339: 334 WEDNESDAY • MAY 18 6:45 Acute
Page 340 and 341: 336 WEDNESDAY • MAY 18 CLINICAL Y
Page 342 and 343: 338 WEDNESDAY • MAY 18 Objectives
Page 344 and 345: 340 WEDNESDAY • MAY 18 D9 BASIC
Page 346 and 347: 342 WEDNESDAY • MAY 18 Oral Prese
Page 348 and 349: 344 WEDNESDAY • MAY 18 10:15 Plas
Page 350 and 351: 346 WEDNESDAY • MAY 18 419 A Nove
Page 352 and 353: 348 WEDNESDAY • MAY 18 216 Simpli
Page 354 and 355: 350 WEDNESDAY • MAY 18 815 Multip
Page 356 and 357: 352 WEDNESDAY • MAY 18 D28 POSTER
Page 358 and 359: 354 WEDNESDAY • MAY 18 720 Repeat
Page 360 and 361: 356 WEDNESDAY • MAY 18 P389 Facil
Page 362 and 363: 358 WEDNESDAY • MAY 18 P439 P440
Page 364 and 365: 360 WEDNESDAY • MAY 18 P10 P11 P1
Page 366 and 367: 362 WEDNESDAY • MAY 18 P52 P53 Fa
Page 368 and 369: 364 WEDNESDAY • MAY 18 P95 P96 P9
Page 370 and 371: 366 WEDNESDAY • MAY 18 P698 P699
Page 372 and 373: 368 WEDNESDAY • MAY 18 D42 THEMAT
Page 374 and 375: 370 WEDNESDAY • MAY 18 P748 Funge
Page 376 and 377:
372 WEDNESDAY • MAY 18 P353 P354
Page 378 and 379:
Page 380 and 381:
376 WEDNESDAY • MAY 18 P808 Facil
Page 382 and 383:
Page 384 and 385:
Page 386 and 387:
Page 388 and 389:
Page 390 and 391:
Page 392 and 393:
Page 394 and 395:
390 WEDNESDAY • MAY 18 11:45 Intr
Page 396 and 397:
392 WEDNESDAY • MAY 18 12:15 Upda
Page 398 and 399:
394 WEDNESDAY • MAY 18 This sessi
Page 400 and 401:
396 WEDNESDAY • MAY 18 1:30 The B
Page 402 and 403:
398 WEDNESDAY • MAY 18 D88 BEHAVI
Page 404 and 405:
400 WEDNESDAY • MAY 18 3:00 Accel
Page 406 and 407:
402 WEDNESDAY • MAY 18 D96 MINI S
Page 408 and 409:
404 WEDNESDAY • MAY 18 604 CARMA3
Page 410 and 411:
406 WEDNESDAY • MAY 18 702 Potent
Page 412 and 413:
408 WEDNESDAY • MAY 18 803 ICU Ac
Page 414 and 415:
410 WEDNESDAY • MAY 18 Chairing:
Page 416 and 417:
412 WEDNESDAY • MAY 18 404 Interm
Page 418:
Where today’s science meets tomor
show all

Final Program

Create successful ePaper yourself

Delete template?

Save as template?